Opthea company info

What does Opthea do?
Opthea (ASX:OPT) is a clinical-stage biopharmaceutical company developing innovative gene therapies to treat a range of ophthalmic diseases, including wet age-related macular degeneration (wet AMD), diabetic macular edema (DME), geographic atrophy (GA), and Stargardt disease. Opthea's key projects include the development and commercialization of its lead product candidates, OPT-302 and OPT-401. OPT-302 is a novel gene therapy for wet AMD that is currently in Phase 3 clinical trials. OPT-401 is a novel gene therapy for DME that is currently in Phase 2 clinical trials. Opthea is also developing OPT-801, a novel gene therapy for GA, and OPT-900, a novel gene therapy for Stargardt disease, both of which are currently in preclinical development.
Opthea company media
Company Snapshot

Is Opthea a public or private company?

key
Ownership
Public

How many people does Opthea employ?

people
Employees
31

What sector is Opthea in?

pie chart
Sector
Health Care

Where is the head office for Opthea?

location pin
Head Office
Victoria, Australia

What year was Opthea founded?

founded flag
Year Founded
1984
What does Opthea specialise in?
/Biotech /Health /Medical /Healthcare /Technology /Eye /Medtech

What are the products and/or services of Opthea?

Overview of Opthea offerings
OPT-302 for wet AMD: OPT-302 is a novel gene therapy for wet age-related macular degeneration (wet AMD). It is currently in Phase 3 clinical trials.
OPT-401 for DME: OPT-401 is a novel gene therapy for diabetic macular edema (DME). It is currently in Phase 2 clinical trials.
OPT-801 for geographic atrophy: OPT-801 is a novel gene therapy for geographic atrophy (GA), a dry form of age-related macular degeneration. It is currently in preclinical development.
OPT-900 for Stargardt disease: OPT-900 is a novel gene therapy for Stargardt disease, a rare genetic eye disease. It is currently in preclinical development.
Commitment to innovation: Opthea is committed to developing innovative gene therapies to treat a range of ophthalmic diseases.
Partnership with leading research institutions and companies: Opthea partners with leading research institutions and companies around the world to develop and commercialise its gene therapies.

Who is in the executive team of Opthea?

Opthea leadership team
  • Dr. Megan  Baldwin M.A.I.C.D., MAICD, Ph.D.
    Dr. Megan Baldwin M.A.I.C.D., MAICD, Ph.D.
    Founder, Chief Innovation Officer & Executive Director
  • Ms. Judith J. Robertson B.A., M.B.A.
    Ms. Judith J. Robertson B.A., M.B.A.
    Chief Commercial Officer
  • Ms. Karen  Adams CPA
    Ms. Karen Adams CPA
    VP of Finance & Company Secretary
  • Dr. Frederic  Guerard M.S., Pharm.D.
    Dr. Frederic Guerard M.S., Pharm.D.
    Chief Executive Officer
  • Mr. Peter F. Lang M.B.A.
    Mr. Peter F. Lang M.B.A.
    Chief Financial Officer
  • Ms. Sarika  Gulhar Ph.D.
    Ms. Sarika Gulhar Ph.D.
    Executive Director of Human Resources
  • Dr. Michael  Gerometta Ph.D.
    Dr. Michael Gerometta Ph.D.
    Head of Chemistry, Manufacturing & Controls Development
  • Mr. Bruno  Gagnon BPHARM, M.Sc.
    Mr. Bruno Gagnon BPHARM, M.Sc.
    Senior Vice President of Global Clinical Operations